JP2022527788A5 - - Google Patents

Info

Publication number
JP2022527788A5
JP2022527788A5 JP2021557927A JP2021557927A JP2022527788A5 JP 2022527788 A5 JP2022527788 A5 JP 2022527788A5 JP 2021557927 A JP2021557927 A JP 2021557927A JP 2021557927 A JP2021557927 A JP 2021557927A JP 2022527788 A5 JP2022527788 A5 JP 2022527788A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
exon
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527788A (ja
JP7650814B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025228 external-priority patent/WO2020205521A1/en
Publication of JP2022527788A publication Critical patent/JP2022527788A/ja
Publication of JP2022527788A5 publication Critical patent/JP2022527788A5/ja
Priority to JP2025038928A priority Critical patent/JP2025090740A/ja
Application granted granted Critical
Publication of JP7650814B2 publication Critical patent/JP7650814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557927A 2019-03-29 2020-03-27 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 Active JP7650814B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025038928A JP2025090740A (ja) 2019-03-29 2025-03-12 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826843P 2019-03-29 2019-03-29
US62/826,843 2019-03-29
PCT/US2020/025228 WO2020205521A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025038928A Division JP2025090740A (ja) 2019-03-29 2025-03-12 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Publications (3)

Publication Number Publication Date
JP2022527788A JP2022527788A (ja) 2022-06-06
JP2022527788A5 true JP2022527788A5 (cg-RX-API-DMAC7.html) 2023-04-04
JP7650814B2 JP7650814B2 (ja) 2025-03-25

Family

ID=72666976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557927A Active JP7650814B2 (ja) 2019-03-29 2020-03-27 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP2025038928A Pending JP2025090740A (ja) 2019-03-29 2025-03-12 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025038928A Pending JP2025090740A (ja) 2019-03-29 2025-03-12 Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Country Status (13)

Country Link
US (2) US20220143023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946293A4 (cg-RX-API-DMAC7.html)
JP (2) JP7650814B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149103A (cg-RX-API-DMAC7.html)
CN (1) CN113939284A (cg-RX-API-DMAC7.html)
AU (1) AU2020254499A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019489A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131864A1 (cg-RX-API-DMAC7.html)
IL (1) IL286742A (cg-RX-API-DMAC7.html)
MX (1) MX2021011948A (cg-RX-API-DMAC7.html)
PH (1) PH12021552395A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110669WA (cg-RX-API-DMAC7.html)
WO (1) WO2020205521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110129434A (zh) * 2018-02-08 2019-08-16 埃提斯生物技术(上海)有限公司 胆汁中生物标志物在诊断恶性肿瘤中的应用
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
JP7709384B2 (ja) * 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
WO2022206929A1 (zh) * 2021-04-01 2022-10-06 上海医药集团股份有限公司 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
KR20230063731A (ko) 2021-11-02 2023-05-09 주식회사 엘지에너지솔루션 전해액의 분할 주입을 포함하는 이차전지의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308658B2 (en) * 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
CA3076915A1 (en) * 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
CN111867586A (zh) * 2018-03-13 2020-10-30 得克萨斯州大学系统董事会 用于治疗具有egfr激活突变的癌症的方法
JP7386174B2 (ja) * 2018-03-27 2023-11-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Similar Documents

Publication Publication Date Title
JP2020502059A5 (cg-RX-API-DMAC7.html)
JP2022529016A5 (cg-RX-API-DMAC7.html)
JP2022529945A5 (cg-RX-API-DMAC7.html)
JP7265985B2 (ja) Egfrまたはher2のエクソン20変異を有するがん細胞に対する抗腫瘍活性を有する化合物
ES2208766T3 (es) Procedimiento de deteccion de mutaciones ki-ras y equipo para llevarlo a cabo.
EP2348111A9 (en) PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF
EP2580322B1 (en) A mek 1 mutation conferring resistance to raf and mek inhibitors
JP2022527499A5 (cg-RX-API-DMAC7.html)
JP2021519306A5 (cg-RX-API-DMAC7.html)
JP2021517894A5 (cg-RX-API-DMAC7.html)
CN104781423A (zh) 对胃癌进行分类的分组方法
CN106148498A (zh) Kras基因突变检测试剂盒及其应用
Cavic et al. Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia
WO2016071477A1 (en) Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
US20180112271A1 (en) Kit For Detecting PIK3CA Gene Mutation
EP3473250B1 (en) Ddr2 mutations as targetable features of melanoma or basal cell carcinoma
US20220305008A1 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
JP2022515128A5 (cg-RX-API-DMAC7.html)
CN106399514A (zh) Nras基因突变检测试剂盒
JP7334194B2 (ja) Tp53突然変異状態及び高頻度突然変異状態に基づくがん治療法
CN114807366A (zh) 一种人肿瘤特异性braf突变检测方法
CN107841793A (zh) 肺癌多基因突变文库的构建方法
Nemtsova et al. Molecular classifications of gastric cancer and their clinical potential
Barranco Key role for microbiota in gut–bone crosstalk
Ahmed 140P Retrospective review of actionable IDH mutations and MGMT promoter methylation among CNS tumors